Individualized tacrolimus therapy: Insights from CYP3A5 polymorphisms and intestinal metabolism

Individualized tacrolimus therapy: Insights from CYP3A5 polymorphisms and intestinal metabolism

Key Clinical Message CYP3A4 and CYP3A5 are the most abundant and important enzymes of the CYP3A subfamily, distributed in the liver, intestinal mucosa and kidney, and involved in tacrolimus metabolism. Here, we report a case of tacrolimus dosage refractoriness due to a genetic polymorphism of CYP3A5...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical Case Reports 2024-09, Vol.12 (9), p.e9416-n/a
Hauptverfasser: Mishima, Mizuki, Yabe, Tomohisa, Kondo, Takaya, Fujimoto, Keiji, Takata, Ryoji, Yokoyama, Hitoshi, Niida, Yo, Tanaka, Tatsuro, Miyazawa, Katsuhito, Furuichi, Kengo
Format: Artikel
Sprache:eng
Schlagworte:
Apixaban
Biopsy
Blood pressure
CYP3A5
Diarrhea
Drug dosages
Enzymes
Genetic aspects
Genetic polymorphisms
Hemodialysis
intestinal absorption
kidney transplantation
Kidney transplants
Liver
Metabolism
Metabolites
Oral administration
Physiological aspects
Polymorphism
Tacrolimus
therapeutic drug monitoring
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Key Clinical Message CYP3A4 and CYP3A5 are the most abundant and important enzymes of the CYP3A subfamily, distributed in the liver, intestinal mucosa and kidney, and involved in tacrolimus metabolism. Here, we report a case of tacrolimus dosage refractoriness due to a genetic polymorphism of CYP3A5.
ISSN:2050-0904
2050-0904
DOI:10.1002/ccr3.9416